Novel association of TM6SF2 rs58542926 genotype with increased serum tyrosine levels and decreased apoB-100 particles in finns

Journal of Lipid Research

Volumn 58, Issue 7, 2017, Pages 1471-1481

  Kim, Daniel Seung ^a   Jackson, Anne U ^a   Li, Yatong K ^a   Stringham, Heather M ^a   Kuusisto, Johanna ^e,g   Kangas, Antti J ^h   Soininen, Pasi ^f,h   Ala Korpela, Mika ^f,h,i   Burant, Charles F ^b,c   Salomaa, Veikko ^j   Boehnke, Michael ^a   Laakso, Markku ^a,e,g   Speliotes, Elizabeth K ^c,d  

^a Center for Statistical Genetics   (United States)

^b Department of Medicine ^*  (United States)

^c Center for Computational Medicine and Bioinformatics   (United States)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^e School of Pharmacy   (United States)

^f UNIVERSITY OF EASTERN FINLAND   (Finland)

^g KUOPIO UNIVERSITY HOSPITAL   (Finland)

^h UNIVERSITY OF OULU   (Finland)

ⁱ UNIVERSITY OF BRISTOL   (United Kingdom)

^j NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

more..

Author keywords

Apolipoprotein B 100; Cardiovascular disease; Epidemiology; Nonalcoholic fatty liver disease; Transmembrane 6 superfamily member 2; Type 2 diabetes; Very low density lipoprotein

Indexed keywords

APOLIPOPROTEIN B100; CHOLESTEROL; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; TYROSINE; VERY LOW DENSITY LIPOPROTEIN; MEMBRANE PROTEIN; TM6SF2 PROTEIN, HUMAN;

ADULT; AGED; AMINO ACID BLOOD LEVEL; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DIABETES MELLITUS; FATTY LIVER; FINN (PEOPLE); GENETIC ASSOCIATION; GENETIC VARIATION; GENOTYPE; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MARKER GENE; METABOLITE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TM6SF2 GENE; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; CROSS-SECTIONAL STUDY; FEMALE; FINLAND; GENETICS; MIDDLE AGED; MUTATION;

APOLIPOPROTEIN B-100; CROSS-SECTIONAL STUDIES; FEMALE; FINLAND; GENOTYPE; HUMANS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MUTATION; POLYMORPHISM, SINGLE NUCLEOTIDE; TYROSINE;

EID: 85021713022     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.P076034     Document Type: Article

References (44)

1. Williams, C. D., J. Stengel, M. I. Asike, D. M. Torres, J. Shaw, M. Contreras, C. L. Landt, and S. A. Harrison. 2011. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology. 140:124-131.
2. McCullough, A. J. 2004. The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease. Clin. Liver Dis. 8:521-533.
3. Yki-Järvinen, H. 2014. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. Lancet Diabetes Endocrinol. 2:901-910.
4. Anstee, Q. M., G. Targher, and C. P. Day. 2013. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat. Rev. Gastroenterol. Hepatol. 10:330-344.
5. Kahali, B., B. Halligan, and E. K. Speliotes. 2015. Insights from genome-wide association analyses of nonalcoholic fatty liver disease. Semin. Liver Dis. 35:375-391.
6. Teslovich, T. M., K. Musunuru, A. V. Smith, A. C. Edmondson, I. M. Stylianou, M. Koseki, J. P. Pirruccello, S. Ripatti, D. I. Chasman, C. J. Willer, et al. 2010. Biological, clinical and population relevance of 95 loci for blood lipids. Nature. 466:707-713.
7. Speliotes, E. K., L. M. Yerges-Armstrong, J. Wu, R. Hernaez, L. J. Kim, C. D. Palmer, V. Gudnason, G. Eiriksdottir, M. E. Garcia, L. J. Launer, et al. 2011. Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet. 7:e1001324.
8. Holmen, O. L., H. Zhang, Y. Fan, D. H. Hovelson, E. M. Schmidt, W. Zhou, Y. Guo, J. Zhang, A. Langhammer, M-L. Løchen, et al. 2014. Systematic evaluation of coding variation identifes a candidate causal variant in TM6SF2 influencing total cholesterol and myocardial infarction risk. Nat. Genet. 46:345-351.
9. Fuchsberger, C., J. Flannick, T. M. Teslovich, A. Mahajan, V. Agarwala, K. J. Gaulton, C. Ma, P. Fontanillas, L. Moutsianas, D. J. McCarthy, et al. 2016. The genetic architecture of type 2 diabetes. Nature. 536:41-47.
10. Kozlitina, J., E. Smagris, S. Stender, B. G. Nordestgaard, H. H. Zhou, A. Tybjaerg-Hansen, T. F. Vogt, H. H. Hobbs, and J. C. Cohen. 2014. Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease. Nat. Genet. 46:352-356.
11. Mahdessian, H., A. Taxiarchis, S. Popov, A. Silveira, A. Franco-Cereceda, A. Hamsten, P. Eriksson, and F. van't Hooft. 2014. TM6SF2 is a regulator of liver fat metabolism infuencing triglyceride secretion and hepatic lipid droplet content. Proc. Natl. Acad. Sci USA. 111:8913-8918.
12. Fan, Y, H. Lu, Y. Guo, T. Zhu, M. T. Garcia-Barrio, Z. Jiang, C. J. Willer, J. Zhang, and Y. E. Chen. 2016. Hepatic transmembrane 6 superfamily member 2 regulates cholesterol metabolism in mice. Gastroenterology. 150:1208-1218.
13. Smagris, E., S. Gilyard, S. BasuRay, J. C. Cohen, and H. H. Hobbs. 2016. Inactivation of Tm6sf2, a gene defective in fatty liver disease, impairs lipidation but not secretion of very low density lipoproteins. J. Biol. Chem. 291:10659-10676.
14. Stancáková, A., M. Javorský, T. Kuulasmaa, S. M. Haffner, J. Kuusisto, and M. Laakso. 2009. Changes in insulin sensitivity and insulin release in relation to glycemia and glucose tolerance in 6, 414 Finnish men. Diabetes. 58:1212-1221.
15. Stancáková, A., M. Civelek, N. K. Saleem, P. Soininen, A. J. Kangas, H. Cederberg, J. Paananen, J. Pihlajamäki, L. L. Bonnycastle, M. A Morken, et al. 2012. Hyperglycemia and a common variant of GCKR are associated with the levels of eight amino acids in 9, 369 Finnish men. Diabetes. 61:1895-1902.
16. Cholesterol Treatment Trialists' (CTT) Collaborators, B. Mihaylova, J. Emberson, L. Blackwell, A. Keech, J. Simes, E. H. Barnes, M. Voysey, A. Gray, R. Collins, et al. 2012. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 380:581-590.
17. Laakso, M., J. Kuusisto, A. Stancáková, T. Kuulasmaa, P. Pajukanta, A. J. Lusis, F. S. Collins, K. Mohlke, and M. Boehnke. 2017. The Metabolic Syndrome in Men study: a resource for studies of metabolic and cardiovascular diseases. J. Lipid Res. 58:481-493.
18. Matsuda, M., and R. A. DeFronzo. 1999. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care. 22:1462-1470.
19. Soininen, P., A. J. Kangas, P. Würtz, T. Suna, and M. Ala-Korpela. 2015. Quantitative serum nuclear magnetic resonance metabolo-mics in cardiovascular epidemiology and genetics. Circ Cardiovasc Genet. 8:192-206.
20. Soininen, P., A. J. Kangas, P. Würtz, T. Tukiainen, T. Tynkkynen, R. Laatikainen, M-R. Jarvelin, M. Kähönen, T. Lehtimäki, J. Viikari, et al. 2009. High-throughput serum NMR metabonomics for cost-effective holistic studies on systemic metabolism. Analyst. 134:1781-1785.
21. Inouye, M., J. Kettunen, P. Soininen, K. Silander, S. Ripatti, L. S. Kumpula, E. Hämäläinen, P. Jousilahti, A. J. Kangas, S. Männistö, et al. 2010. Metabonomic, transcriptomic, and genomic variation of a population cohort. Mol. Syst. Biol. 6:441-450.
22. Okazaki, M., S. Usui, M. Ishigami, N. Sakai, T. Nakamura, Y. Matsuzawa, and S. Yamashita. 2005. Identification of unique lipoprotein subclasses for visceral obesity by component analysis of cholesterol profile in high-performance liquid chromatography. Arterioscler. Thromb. Vasc. Biol. 25:578-584.
23. Delaneau, O., J-F. Zagury, and J. Marchini. 2013. Improved whole-chromosome phasing for disease and population genetic studies. Nat. Methods. 10:5-6.
24. Fuchsberger, C, G. R. Abecasis, and D. A. Hinds. 2015. minimac2: faster genotype imputation. Bioinformatics. 31:782-784.
25. Vartiainen, E., T. Laatikainen, M. Peltonen, A. Juolevi, S. Mannisto, J. Sundvall, P. Jousilahti, V. Salomaa, L. Valsta, and P. Puska. 2010. Thirty-fve-year trends in cardiovascular risk factors in Finland. Int. J. Epidemiol. 39:504-518.
26. Marttinen, P., M. Pirinen, A-P. Sarin, J. Gillberg, J. Kettunen, I. Surakka, A. J. Kangas, P. Soininen, P. O'Reilly, M. Kaakinen, et al. 2014. Assessing multivariate gene-metabolome associations with rare variants using Bayesian reduced rank regression. Bioinformatics. 30:2026-2034.
27. Vogt, S., S. Wahl, J. Kettunen, S. Breitner, G. Kastenmüller, C. Gieger, K. Suhre, M. Waldenberger, J. Kratzsch, M. Perola, et al. 2016. Characterization of the metabolic profile associated with serum 25-hydroxyvitamin D: a cross-sectional analysis in population-based data. Int. J. Epidemiol. 45:1469-1481.
28. Würtz, P., A. S. Havulinna, P. Soininen, T. Tynkkynen, D. Prieto-Merino, T. Tillin, A. Ghorbani, A. Artati, Q. Wang, M. Tiainen, et al. 2015. Metabolite profiling and cardiovascular event risk: a prospective study of 3 population-based cohorts. Circulation. 131:774-785.
29. Sulkava, S., H. M. Ollila, K. Ahola, T. Partonen, K. Viitasalo, J. Kettunen, M. Lappalainen, M. Kivimäki, J. Vahtera, J. Lindstrom, et al. 2013. Genome-wide scan of job-related exhaustion with three replication studies implicate a susceptibility variant at the UST gene locus. Hum. Mol. Genet. 22:3363-3372.
30. Dixon, W. J., and J. W. Tukey. 1968. Approximate behavior of the distribution of Winsorized t (Trimming/Winsorization 2). Technometrics. 10:83-98.
31. Buch, S., F. Stickel, E. Trépo, M. Way, A. Herrmann, H. D. Nischalke, M. Brosch, J. Rosendahl, T. Berg, M. Ridinger, et al. 2015. A genome-wide association study confirms PNPLA3 and identifes TM6SF2 and MBOAT7 as risk loci for alcohol-related cirrhosis. Nat. Genet. 47:1443-1448.
32. Milano, M., A. Aghemo, R. M. Mancina, J. Fischer, P. Dongiovanni, S. De Nicola, A. L. Fracanzani, R. D'Ambrosio, M. Maggioni, R. De Francesco, et al. 2015. Transmembrane 6 superfamily member 2 gene E167K variant impacts on steatosis and liver damage in chronic hepatitis C patients. Hepatology. 62:111-117.
33. Coppola, N., Z. Rosa, G. Cirillo, M. Stanzione, M. Macera, A. Boemio, A. Grandone, M. Pisaturo, A. Marrone, L. E. Adinolfi, et al. 2015. TM6SF2 E167K variant is associated with severe steatosis in chronic hepatitis C, regardless of PNPLA3 polymorphism. Liver Int. 35:1959-1963.
34. Pirola, C. J., and S. Sookoian. 2015. The dual and opposite role of the TM6SF2-rs58542926 variant in protecting against cardiovascular disease and conferring risk for nonalcoholic fatty liver: a Meta-Analysis. Hepatology. 62:1742-1756.
35. Kahali, B., Y-L. Liu, A. K Daly, C. P. Day, Q. M. Anstee, and E. K Speliotes. 2015. TM6SF2: catch-22 in the fight against nonalcoholic fatty liver disease and cardiovascular disease? Gastroenterology. 148:679-684.
36. Sookoian, S., and C. J. Pirola. 2016. The exact mechanism by which hepatic transmembrane 6 superfamily member 2 modulates triglyceride metabolism is still uncertain. Gastroenterology. 151:1033-1034.
37. Elias, N., B. W. Patterson, and G. Schonfeld. 1999. Decreased production rates of VLDL triglycerides and ApoB-100 in subjects heterozygous for familial hypobetalipoproteinemia. Arterioscler. Thromb. Vasc. Biol. 19:2714-2721.
38. Gordon, S. M., H. Li, X. Zhu, A. S. Shah, L. J. Lu, and W. S. Davidson. 2015. A comparison of the mouse and human lipoproteome: suitability of the mouse model for studies of human lipoproteins. J. Proteome Res. 14:2686-2695.
39. Camus, M. C., M. J. Chapman, P. Forgez, and P. M. Laplaud. 1983. Distribution and characterization of the serum lipoproteins and apoproteins in the mouse, Mus musculus. J. Lipid Res. 24:1210-1228.
40. Stergachis, A. B., S. Neph, R. Sandstrom, E. Haugen, A. P. Reynolds, M. Zhang, R. Byron, T. Canfield, S. Stelhing-Sun, K. Lee, et al. 2014. Conservation of trans-acting circuitry during mammalian regulatory evolution. Nature. 515:365-370.
41. Dietschy, J. M., and S. D. Turley. 2002. Control of cholesterol turnover in the mouse. J. Biol. Chem. 277:3801-3804.
42. Würtz, P., P. Soininen, A. J. Kangas, T. Rönnemaa, T. Lehtimäki, M. Kähönen, J. S. Viikari, O. T. Raitakari, and M. Ala-Korpela. 2013. Branched-chain and aromatic amino acids are predictors of insulin resistance in young adults. Diabetes Care. 36:648-655.
43. Würtz, P., M. Tiainen, V-P. Mäkinen, A. J. Kangas, P. Soininen, J. Saltevo, S. Keinanen-Kiukaanniemi, P. Mäntyselkä, T. Lehtimäki, M. Laakso, et al. 2012. Circulating metabolite predictors of glycemia in middle-aged men and women. Diabetes Care. 35:1749-1756.
44. Würtz, P., Q. Wang, A. J. Kangas, R. C. Richmond, J. Skarp, M. Tiainen, T. Tynkkynen, P. Soininen, A. S. Havulinna, M. Kaakinen, et al. 2014. Metabolic signatures of adiposity in young adults: Mendelian randomization analysis and effects of weight change. PLoS Med. 11:e1001765.